Shots:

• Xencor to receive upfront- milestones and royalties on successful development and commercialization of product. Gilead to get exclusive license rights for GS-9722 & up to three additional anti-HIV Abs and will be responsible for research- development- regulatory and commercial activities and all costs
• Gilead will get rights to access Xencor’s Xtend extended half-life and Cytotoxic XmAb Fc platforms to develop and commercialize its GS-9722 and the agreement will further expand ability of XmAb technologies to develop therapies for HIV
• Xtend XmAb Fc is targeted to improve the immune system’s elimination of tumor and other pathologic cells by ADCC

Click here to read full press release/ article

 Ref: Xencor | Image: Gilead